Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Abstract LBA37)
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and left-sided metastatic colon cancer.
Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)
Shou-Ching Tang, MD, PhD, of the Georgia Cancer Center, discusses findings on a novel peptide–paclitaxel conjugate that crosses the blood-brain barrier and shows activity in breast cancer patients with recurrent central nervous system metastases. (Abstract 324O)
Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
